

News Releases

All Years

Search

Go

[Advanced Search](#)

OCT 18, 2023

Inhibrx Announces Participation in Upcoming Scientific Conferences

AUG 29, 2023

Inhibrx Announces \$200 Million Private Placement Financing

AUG 7, 2023

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

MAY 8, 2023

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

APR 26, 2023

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

MAR 6, 2023

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

JAN 4, 2023

NorthStar Medical Receives FDA Approval and Inhibrx Enters into

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

NOV 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference

NOV 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

NOV 7, 2022

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Show 10  per page

«	1	2	3	4	5	6	7	8	»
-------------------	-------------------	-------------------	-------------------	----------	-------------------	-------------------	-------------------	-------------------	-------------------



<https://inhibrxbiosciences.investorroom.com/news-releases?l=10&o=30>